Secoemestrin C Ameliorates Psoriasis-like Skin Inflammation in Mice by Suppressing the TNF-α/NF-κB Signaling Pathway

Abstract

Objective

Secoemestrin C (SC), an epitetrathiodioxopiperazine isolated from Aspergillus nidulans, has been previously reported to have immunomodulatory and hepatoprotective effects against acute autoimmune hepatitis. However, the effect of SC on regulating the inflammation and its underlying mechanisms in the pathogenesis of psoriasis remain unclear. This study aimed to evaluate the effects of SC on inflammatory dermatosis both in vitro and in vivo.

Methods

In vitro, HaCaT cells were induced with tumor necrosis factor-alpha (TNF-α, 10 ng/mL) to establish an inflammatory injury model, and the expression of nuclear transcription factor-κB (NF-κB) pathway components was measured using qRT-PCR and Western blotting. An in vivo mouse model of imiquimod (IMQ)-induced psoriasis-like skin inflammation was used to evaluate the effectiveness of SC in alleviating psoriasis.

Results

SC significantly blocked the activation of NF-κB signaling in TNF-α-stimulated HaCaT cells. In addition, systemic and local administration of SC improved psoriatic dermatitis in the IMQ-induced mouse model. SC reduced skin scale and significantly inhibited the secretion of inflammatory factors in skin lesions.

Conclusion

The protective effect of SC against psoriatic-associated inflammation reveals its potential therapeutic value for treating psoriasis.

Keywords

secoemestrin C (SC) / psoriasis / tumor necrosis factor-alpha (TNF-α) / nuclear transcription factor-κB (NF-κB) / inflammation

References

[1]	Parisi R, Symmons DPM, Griffiths CEM, et al. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol, 2013,133(2):377–385
[2]	Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol, 2017,31(2):205–212
[3]	Kamiya K, Kishimoto M, Sugai J, et al. Risk factors for the development of psoriasis. Int J Mol Sci, 2019,20(18):4347
[4]	Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol, 2019,80(1):27–40
[5]	Tsuruta D. NF-kappaB links keratinocytes and lymphocytes in the pathogenesis of psoriasis. Recent Pat Inflamm Allergy Drug Discov, 2009,3(1):40–48
[6]	Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci, 2020,21(20):7488
[7]	Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med, 2001,344(12):907–916
[8]	Duan H, Koga T, Kohda F, et al. Interleukin-8-positive neutrophils in psoriasis. J Dermatol Sci, 2001,26(2):119–124
[9]	Giustizieri ML, Mascia F, Frezzolini A, et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol, 2001,107(5):871–877
[10]	Tan X, Sun L, Li Q, et al. Secoemestrin C inhibits activation of NKT/conventional T cells and protects against concanavalin A-induced autoimmune hepatitis in mice. Am J Transl Res, 2020,12(7):3389–3401
[11]	Komine M, Rao LS, Freedberg IM, et al. Interleukin-1 induces transcription of keratin K6 in human epidermal keratinocytes. J Invest Dermatol, 2001,116(2):330–338
[12]	Gillitzer R, Ritter U, Spandau U, et al. Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol, 1996,107(5):778–782
[13]	Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis, 2005,64(Suppl 2):ii18–23; discussion ii24–15
[14]	Singh R, Koppu S, Perche PO, et al. The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications. Int J Mol Sci, 2021,22(23):12793
[15]	Shan X, Chen L, Cao M, et al. Effects of human soluble BAFF synthesized in Escherichia coli on CD4+ and CD8+ T lymphocytes as well as NK cells in mice. Physiol Res, 2006,55(3):301–307
[16]	Li Y, Li X F, Ma Y, et al. Changes in the levels of CD4+ and CD8+ T-lymphocytes after strontium-89 chloride therapy for painful bone metastases in patients correlate with treatment efficacy. Cancer Biother Radiopharm, 2007,22(3):367–373
[17]	Zhang R, Wang YH, Shi X, et al. Sortilin regulates keratinocyte proliferation and apoptosis through the PI3K-AKT signaling pathway. Life Sci, 2021,278: 119630
[18]	Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell, 2008,132(3):344–362
[19]	Cai Y, Xue F, Quan C, et al. A critical role of the IL-1β-IL-1R signaling pathway in skin inflammation and psoriasis pathogenesis. J Invest Dermatol, 2019,139(1):146–156
[20]	Su JY, Luo X, Zhang XJ, et al. Immunosuppressive activity of pogostone on T cells: Blocking proliferation via S phase arrest. Int Immunopharmacol, 2015,26(2):328–337
[21]	Yang Y, Zhang Y, Chen X, et al. Khasianine ameliorates psoriasis-like skin inflammation and represses TNF-α/NF-κB axis mediated transactivation of IL-17A and IL-33 in keratinocytes. J Ethnopharmacol, 2022,292:115124
[22]	Campanati A, Orciani M, Sorgentoni G, et al. Indirect co-cultures of healthy mesenchymal stem cells restore the physiological phenotypical profile of psoriatic mesenchymal stem cells. Clin Exp Immunol, 2018,193(2):234–240
[23]	Yang C, Zhang J, Ding M, et al. Ki67 targeted strategies for cancer therapy. Clin Transl Oncol, 2018,20(5):570–575
[24]	Goff KL, Karimkhani C, Boyers LN, et al. The global burden of psoriatic skin disease. Br J Dermatol, 2015,172(6):1665–1668
[25]	Campanati A, Ganzetti G, Sario AD, et al. The effect of etanercept on hepatic fibrosis risk in patients with nonalcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol, 2013,48(7):839–846
[26]	Bach E, Nielsen RR, Vendelbo MH, et al. Direct effects of TNF-a on local fuel metabolism and cytokine levels in the placebo-controlled, bilaterally infused human leg: increased insulin sensitivity, increased net protein breakdown, and increased IL-6 release. Diabetes, 2013,62(12):4023–4029
[27]	Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther, 2008,117(2):244–279
[28]	Vergou T, Moustou AE, Sfikakis PP, et al. Pharmacodynamics of TNF-α inhibitors in psoriasis. Expert Rev Clin Pharmacol, 2011,4(4):515–523
[29]	Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood, 2012,119(3):651–665
[30]	Calip GS, Patel PR, Adimadhyam S, et al. Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. Int J Cancer, 2018,143(5):1062–1071
[31]	Fagerli KM, Kearsley-Fleet L, Mercer LK, et al. Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford), 2019,58(1):80–85
[32]	Sedger LM, McDermott MF. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants-past, present and future. Cytokine Growth Factor Rev, 2014,25(4):453–472